Inactive Instrument
Pluristem Therapeutics Share Price Nasdaq
Stocks
Biotechnology & Medical Research
| Market Cap | 12.34M 11.02M 10.28M 9.34M 17.58M 1.2B 17.75M 123M 48.29M 608M 46.35M 45.34M 1.95B | P/E 2025 |
-1.39x | P/E 2026 | -0.85x |
|---|---|---|---|---|---|
| Enterprise Value | 39.45M 35.23M 32.87M 29.86M 56.18M 3.82B 56.73M 395M 154M 1.94B 148M 145M 6.24B | EV / Sales 2025 |
39,078,124x | EV / Sales 2026 | 48,878,101x |
| Free-Float |
57.48% | Yield 2025 * |
-
| Yield 2026 | - |
| 1 day | +3.38% |
| Manager | Title | Age | Since |
|---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 54 | 28/03/2017 |
Liat Zalts
DFI | Director of Finance/CFO | 42 | 30/11/2022 |
Ori Shalem
COO | Chief Operating Officer | - | 31/12/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Yaky Yanay
BRD | Director/Board Member | 54 | 31/01/2015 |
| Director/Board Member | 56 | 05/01/2021 | |
| Director/Board Member | 64 | 31/05/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.38% | -1.33% | - | - | 12.34M | ||
| -3.19% | -3.19% | +44.60% | +87.98% | 72.13B | ||
| +3.71% | -10.45% | +5.13% | +56.36% | 49.41B | ||
| +1.99% | +1.34% | +5.33% | +33.61% | 47.24B | ||
| -1.59% | -8.25% | +298.16% | +644.35% | 40.32B | ||
| +0.94% | +0.26% | +27.52% | +29.73% | 42.61B | ||
| +0.64% | -2.41% | -0.27% | +101.36% | 39.81B | ||
| -2.13% | -2.18% | +7.51% | +50.31% | 30.52B | ||
| +2.82% | -4.44% | -11.37% | -15.29% | 23.13B | ||
| +3.40% | +7.93% | +17.97% | -0.04% | 21.09B | ||
| Average | +0.93% | -3.66% | +43.84% | +109.82% | 40.7B | |
| Weighted average by Cap. | +0.27% | -3.85% | +47.10% | +117.90% |
| 2025 | 2026 | |
|---|---|---|
| Net sales | 1.34 1.19 1.11 1.01 1.9 129.39 1.92 13.36 5.23 65.75 5.02 4.91 211.46 | 1.02 0.91 0.85 0.77 1.45 98.4 1.46 10.16 3.97 50 3.81 3.73 160.81 |
| Net income | -22.58M -20.17M -18.81M -17.09M -32.16M -2.19B -32.47M -226M -88.34M -1.11B -84.79M -82.95M -3.57B | -23.82M -21.27M -19.84M -18.03M -33.92M -2.31B -34.25M -238M -93.19M -1.17B -89.44M -87.5M -3.77B |
| Net Debt | 13.44M 12M 11.19M 10.17M 19.13M 1.3B 19.32M 134M 52.57M 661M 50.45M 49.36M 2.13B | 27.11M 24.21M 22.58M 20.52M 38.61M 2.63B 38.98M 271M 106M 1.33B 102M 99.58M 4.29B |
Employees
-
















